The trial found no significant difference in pain or function outcomes between bone marrow injections and sham procedures over 12 months, but also had important limitations.
New peer-reviewed review argues that Wharton's Jelly derived mesenchymal stem cells offer a novel, non-invasive option for many regenerative therapies.
Researchers are exploring whether stem cell-derived extracellular vesicles could offer safer, targeted therapies for respiratory diseases, but technical hurdles remain.
